Corinne Johnson
Stock Analyst at Goldman Sachs
Total Price Targets
8
Stocks Covered
6
Sectors
Healthcare
Most Recent
Oct 17, 2025
Notable Calls (Last 12 Months)
Stocks Covered by Corinne Johnson
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | $139.00 | $99.36 | +39.9% | 2 | Oct 17, 2025 |
| AVBP | ArriVent BioPharma, Inc. | $33.00 | $30.05 | +9.8% | 1 | Jul 10, 2025 |
| HRMY | Harmony Biosciences Holdings, Inc. | $33.00 | $35.05 | -5.9% | 1 | Jul 10, 2025 |
| SNDX | Syndax Pharmaceuticals, Inc. | $18.00 | $18.95 | -5.0% | 1 | Jul 10, 2025 |
| CGON | CG Oncology Inc. | $52.00 | $70.81 | -26.6% | 2 | Sep 16, 2024 |
| IMVT | Immunovant, Inc. | $50.00 | $38.43 | +30.1% | 1 | Mar 13, 2024 |
Recent Activity
- Oct 17, 2025— Set$139.00price target onRYTM(Rhythm Pharmaceuticals, Inc.)
- Jul 10, 2025— Set$33.00price target onAVBP(ArriVent BioPharma, Inc.)
- Jul 10, 2025— Set$33.00price target onHRMY(Harmony Biosciences Holdings, Inc.)
- Jul 10, 2025— Set$97.00price target onRYTM(Rhythm Pharmaceuticals, Inc.)
- Jul 10, 2025— Set$18.00price target onSNDX(Syndax Pharmaceuticals, Inc.)
- Sep 16, 2024— Set$52.00price target onCGON(CG Oncology Inc.)
- May 13, 2024— Set$50.00price target onCGON(CG Oncology Inc.)
- Mar 13, 2024— Set$50.00price target onIMVT(Immunovant, Inc.)
Frequently Asked Questions
Who is Corinne Johnson?
Corinne Johnson is a stock analyst at Goldman Sachs covering 6 stocks primarily in Healthcare. They have issued 8 price targets since Mar 13, 2024.
What stocks does Corinne Johnson cover?
Corinne Johnson currently covers 6 stocks, including RYTM, CGON, AVBP, HRMY, SNDX.
What is Corinne Johnson's latest price target?
Corinne Johnson's most recent price target was $139.00 on RYTM (Rhythm Pharmaceuticals, Inc.), set on Oct 17, 2025.
What is Corinne Johnson's highest price target?
Corinne Johnson's highest issued price target is $139.00 on RYTM, set on Oct 17, 2025.
More Analysts at Goldman Sachs
Coverage based on publicly published price targets. Not investment advice.